IUSCCC Grand Rounds 12/2/2022: " Preclinical Development of Agents with Combined Antitumor and Base Anabolic Activity for Multiple Myeloma" Attaya Suvannasankha, MD

views comments

Policy

" Preclinical Development of Agents with Combined Antitumor and Base Anabolic Activity for Multiple Myeloma" Attaya Suvannasankha, MD, Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology IUSM

Tags

IUSCCC Grand Rounds 12/2/2022: " Preclinical Development of Agents with Combined Antitumor and Base Anabolic Activity for Multiple Myeloma" Attaya Suvannasankha, MD

Policy

Related Media